Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Cadrenal Therapeutics  / Equity Bottom-Up

<ul><li>On May 8, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the first quarter of 2025 and provided a business update.</li><li>The company has been laying the groundwork for a Phase 3 trial of tecarfarin in patients with left ventricular assist devices (LVAD).</li><li>In support of this, Cadrenal recently announced a collaboration agreement with Abbott to support the planned TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.</li></ul>

On May 8, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the first quarter of 2025 and provided a business update.The company has been laying the groundwork for a Phase 3 trial of tecarfarin in patients with left ventricular assist devices (LVAD).In support of this, Cadrenal recently announced a collaboration agreement with Abbott to support the planned TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.

CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin 